Samsung Group, South Korea's leading conglomerate, has taken a significant step toward driving forward its newly-established biopharmaceuticals business, an emerging sector expected to become one of the company's future growth engines. Samsung Bioepis, the conglomerate's biotechnology research and development unit, said Monday that it had gained approval from the Ministry of Food and Drug Safety to begin selling Brenzys, its biosimilar copy of Pfizer's rheumatoid arthritis treatment Enbrel, in South Korea.